The PARALLAX study points to potential benefits from sacubitril/valsartan in heart failure with preserved ejection fraction, which has no approved treatments. A year ago, the PARAGON-HF trial for sacubitril/valsartan came within a whisker of achieving its primary end point and an elusive…